Doxofylline是一种口服有效的PDE IV抑制剂和A1AR拮抗剂。它通过抑制线粒体ROS产生及改善NLRP3-TXNIP炎症体激活等途径减轻上皮炎症,可用于哮喘、COPD及支气管痉挛的研究。
|
英文别名 (English Synonym) |
Doxofylline |
|
中文名称 (Chinese Name) |
多索茶碱 |
|
靶点 (Target) |
PDE |
|
通路 (Pathway) |
Protease/Metabolic Enzyme |
|
CAS号 (CAS NO.) |
69975-86-6 |
|
分子式 (Formula) |
C11H14N4O4 |
|
分子量 (Molecular Weight) |
266.25 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Jiao P, Li W, Shen L, Li Y, Yu L, Liu Z. The protective effect of doxofylline against lipopolysaccharides (LPS)-induced activation of NLRP3 inflammasome is mediated by SIRT1 in human pulmonary bronchial epithelial cells. Artif Cells Nanomed Biotechnol. 2020 Dec,48(1):687-694. doi: 10.1080/21691401.2020.1730391. PMID: 32098511.[2]Riffo-Vasquez Y, Man F, Page CP. Doxofylline, a novofylline inhibits lung inflammation induced by lipopolysacharide in the mouse. Pulm Pharmacol Ther. 2014 Apr,27(2):170-8. doi: 10.1016/j.pupt.2014.01.001. Epub 2014 Jan 21. PMID: 24456641.
